Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Endoplasmic reticulum stress and inflammation in the central nervous system.

Sprenkle NT, Sims SG, Sánchez CL, Meares GP.

Mol Neurodegener. 2017 May 25;12(1):42. doi: 10.1186/s13024-017-0183-y. Review.

2.

Models of LRRK2-Associated Parkinson's Disease.

Xiong Y, Dawson TM, Dawson VL.

Adv Neurobiol. 2017;14:163-191. doi: 10.1007/978-3-319-49969-7_9.

3.

Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.

Nguyen AP, Moore DJ.

Adv Neurobiol. 2017;14:71-88. doi: 10.1007/978-3-319-49969-7_4.

4.

Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.

Islam MS, Moore DJ.

Biochem Soc Trans. 2017 Feb 8;45(1):163-172. doi: 10.1042/BST20160264. Review.

PMID:
28202670
5.

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.

Qin Q, Zhi LT, Li XT, Yue ZY, Li GZ, Zhang H.

CNS Neurosci Ther. 2017 Feb;23(2):162-173. doi: 10.1111/cns.12660. Epub 2016 Dec 9.

6.

LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives.

Atashrazm F, Dzamko N.

Clin Pharmacol. 2016 Oct 20;8:177-189. eCollection 2016. Review.

7.

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation.

Lobbestael E, Civiero L, De Wit T, Taymans JM, Greggio E, Baekelandt V.

Sci Rep. 2016 Sep 23;6:33897. doi: 10.1038/srep33897.

8.

Protein Kinases and Parkinson's Disease.

Mehdi SJ, Rosas-Hernandez H, Cuevas E, Lantz SM, Barger SW, Sarkar S, Paule MG, Ali SF, Imam SZ.

Int J Mol Sci. 2016 Sep 20;17(9). pii: E1585. Review.

9.
10.

Structure, function, and leucine-rich repeat kinase 2: On the importance of reproducibility in understanding Parkinson's disease.

Cookson MR.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8346-8. doi: 10.1073/pnas.1609311113. Epub 2016 Jul 15. No abstract available.

11.

Emerging preclinical pharmacological targets for Parkinson's disease.

More SV, Choi DK.

Oncotarget. 2016 May 17;7(20):29835-63. doi: 10.18632/oncotarget.8104. Review.

12.

Decoding Parkinson's Disease Pathogenesis: The Role of Deregulated mRNA Translation.

Martin I.

J Parkinsons Dis. 2016;6(1):17-27. doi: 10.3233/JPD-150738. Review.

13.

The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease.

Kang JF, Tang BS, Guo JF.

Stem Cells Int. 2016;2016:4126214. doi: 10.1155/2016/4126214. Epub 2016 Jan 6. Review.

14.

The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.

Langston RG, Rudenko IN, Cookson MR.

Biochem J. 2016 Feb 1;473(3):221-32. doi: 10.1042/BJ20150985. Review.

15.

LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.

Sloan M, Alegre-Abarrategui J, Potgieter D, Kaufmann AK, Exley R, Deltheil T, Threlfell S, Connor-Robson N, Brimblecombe K, Wallings R, Cioroch M, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Dodson PD, Wade-Martins R.

Hum Mol Genet. 2016 Mar 1;25(5):951-63. doi: 10.1093/hmg/ddv628. Epub 2016 Jan 6.

16.

Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.

Liu J, Li T, Thomas JM, Pei Z, Jiang H, Engelender S, Ross CA, Smith WW.

Hum Mol Genet. 2016 Feb 15;25(4):672-80. doi: 10.1093/hmg/ddv504. Epub 2016 Jan 6.

17.

Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.

Schwab AJ, Ebert AD.

Stem Cell Reports. 2015 Dec 8;5(6):1039-1052. doi: 10.1016/j.stemcr.2015.11.004.

18.

14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.

Lavalley NJ, Slone SR, Ding H, West AB, Yacoubian TA.

Hum Mol Genet. 2016 Jan 1;25(1):109-22. doi: 10.1093/hmg/ddv453. Epub 2015 Nov 5.

19.

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Taymans JM, Greggio E.

Curr Neuropharmacol. 2016;14(3):214-25. Review.

20.

Combination therapies: The next logical Step for the treatment of synucleinopathies?

Valera E, Masliah E.

Mov Disord. 2016 Feb;31(2):225-34. doi: 10.1002/mds.26428. Epub 2015 Sep 21. Review.

Supplemental Content

Support Center